BioVie Inc. announced on May 5, 2025, the formation of its Corporate Advisory Board, comprising seven members with diverse expertise. The board includes Dr. Zaldy Tan, a brain health leader from Cedars-Sinai, Justina Omokhua, a marketing expert from Parkwood, and Tim Gardner, a co-founder of Neuralink.
Each board member brings significant experience and cross-sector expertise aimed at advancing BioVie's mission to transform treatment for Alzheimer’s, Parkinson’s, and other neuroinflammatory disorders. Their collective knowledge is expected to be instrumental in unlocking value and reshaping patient care.
This strategic move is designed to provide BioVie with enhanced guidance as it progresses its lead candidate, bezisterim, through Phase 2 trials for early Parkinson’s disease and Long COVID, and plans future clinical development for its Alzheimer’s disease and ascites programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.